Aleph-2

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-2's dose as 4 to 8mg orally and its duration as 8 to 16hours. The effects of Aleph-2 have been reported to include "almost no visual phenomena" to "extraordinary visuals and interpretations", visual distortion and movement, enhanced auditory and tactile perception, and a sensation of physical warmth, and residual shakiness and muscle tremors, among others. There is an unpredictability with the dosing and effects of Aleph-2, such that one person who took 4mg had strong effects including ending up in a fetal position, in relative hibernation for several hours, and with substantial amnesia, whereas another person who took 8mg experienced only a bare threshold including slight lightheadedness. ==Interactions==

Pharmacodynamics Aleph-2 acts as a serotonin 5-HT2 receptor agonist. ==Chemistry==

Synthesis The chemical synthesis of Aleph-2 has been described. Analogues Analogues of Aleph-2 include Aleph, Aleph-4, Aleph-6, Aleph-7, and 2C-T-2, among others. ==History==

Aleph-2 was first described in the scientific literature by Alexander Shulgin in 1978. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). Aleph-2 was encountered as a novel designer drug in Europe in 2023. ==Society and culture==

Legal status Canada Aleph-2 is a controlled substance in Canada under phenethylamine blanket-ban language. United States Aleph-2 is not an explicitly controlled substance in the United States. == See also ==